VA - Psyched: $100M For MDMA Therapy VA Funds 2024 Watchlist Reform Updates And More | Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).
MAPS has incubated the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application to the FDA. Find out more HERE.
Veterans Affairs, After Decades, Will Fund Psychedelic Research For Vets With PTSD And Depression
In a groundbreaking move, the U.S. Department of Veterans Affairs (VA) is launching new studies on using psychedelic compounds to treat post-traumatic stress disorder (PTSD) and depression among military veterans. This marks a significant shift for the VA, representing the first such research since the 1960s, reported Military Times.
This new VA-backed effort will delve deeper into "the effectiveness and safety of using MDMA and psilocybin-augmented psychotherapy in veterans," as the VA release outlined. Keep reading HERE.
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Key players and influential figures worldwide are helping drive innovation and acceptance around psychedelic medicines. Trailblazers in this industry come from diverse backgrounds including scientists, investors, advocates, publicists, journalists and policy reformers.